MBX-500, a Hybrid Antibiotic with In Vitro and In Vivo Efficacy against Toxigenic Clostridium difficile
- 1 September 2012
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (9) , 4786-4792
Abstract
Clostridium difficile infection (CDI) causes moderate to severe disease, resulting in diarrhea and pseudomembranous colitis. CDI is difficult to treat due to production of inflammation-inducing toxins, resistance development, and high probability of recurrence. Only two antibiotics are approved for the treatment of CDI, and the pipeline for therapeutic agents contains few new drugs. MBX-500 is a hybrid antibacterial, composed of an anilinouracil DNA polymerase inhibitor linked to a fluoroquinolone DNA gyrase/topoisomerase inhibitor, with potential as a new therapeutic for CDI treatment. Since MBX-500 inhibits three bacterial targets, it has been previously shown to be minimally susceptible to resistance development. In the present study, the in vitro and in vivo efficacies of MBX-500 were explored against the Gram-positive anaerobe, C. difficile . MBX-500 displayed potency across nearly 50 isolates, including those of the fluoroquinolone-resistant, toxin-overproducing NAP1/027 ribotype, performing as well as comparator antibiotics vancomycin and metronidazole. Furthermore, MBX-500 was a narrow-spectrum agent, displaying poor activity against many other gut anaerobes. MBX-500 was active in acute and recurrent infections in a toxigenic hamster model of CDI, exhibiting full protection against acute infections and prevention of recurrence in 70% of the animals. Hamsters treated with MBX-500 displayed significantly greater weight gain than did those treated with vancomycin. Finally, MBX-500 was efficacious in a murine model of CDI, again demonstrating a fully protective effect and permitting near-normal weight gain in the treated animals. These selective anti-CDI features support the further development of MBX 500 for the treatment of CDI.Keywords
This publication has 29 references indexed in Scilit:
- Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile InfectionsClinical Therapeutics, 2012
- In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2008
- Comparative Efficacies of Rifaximin and Vancomycin for Treatment of Clostridium difficile -Associated Diarrhea and Prevention of Disease Recurrence in HamstersAntimicrobial Agents and Chemotherapy, 2008
- Frequent Emergence of Resistance in Clostridium difficile during Treatment of C. difficile -Associated Diarrhea with Fusidic AcidAntimicrobial Agents and Chemotherapy, 2006
- Binary Toxin–Producing, Large Clostridial Toxin–NegativeClostridium difficileStrains Are Enterotoxic but Do Not Cause Disease in HamstersThe Journal of Infectious Diseases, 2006
- Rifalazil Treats and Prevents Relapse of Clostridium difficile -Associated Diarrhea in HamstersAntimicrobial Agents and Chemotherapy, 2004
- Reassessment of Clostridium difficile Susceptibility to Metronidazole and VancomycinAntimicrobial Agents and Chemotherapy, 2002
- Dual β-lactam-fluoroquinolone compounds: a novel approach to antibacterial treatmentExpert Opinion on Investigational Drugs, 1997
- Treatment of relapsingClostridium difficile diarrhoea by administration of a non-toxigenic strainEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987
- Antibiotic-Associated Pseudomembranous Colitis Due to Toxin-Producing ClostridiaNew England Journal of Medicine, 1978